MA52946A - Composés - Google Patents

Composés

Info

Publication number
MA52946A
MA52946A MA052946A MA52946A MA52946A MA 52946 A MA52946 A MA 52946A MA 052946 A MA052946 A MA 052946A MA 52946 A MA52946 A MA 52946A MA 52946 A MA52946 A MA 52946A
Authority
MA
Morocco
Prior art keywords
compounds
Prior art date
Application number
MA052946A
Other languages
English (en)
Other versions
MA52946B1 (fr
Inventor
Steven Boakes
Pamela Brown
Scott Coleman
Michael Dawson
Esther Duperchy
Roy Lester
Dean Rivers
Mona Simonovic
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of MA52946A publication Critical patent/MA52946A/fr
Publication of MA52946B1 publication Critical patent/MA52946B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62Polymyxins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA52946A 2018-06-25 2019-06-25 Composés MA52946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (fr) 2018-06-25 2019-06-25 Composés

Publications (2)

Publication Number Publication Date
MA52946A true MA52946A (fr) 2021-04-28
MA52946B1 MA52946B1 (fr) 2024-03-29

Family

ID=67107423

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52946A MA52946B1 (fr) 2018-06-25 2019-06-25 Composés

Country Status (30)

Country Link
US (2) US11459357B2 (fr)
EP (2) EP4316504A3 (fr)
JP (2) JP7488774B2 (fr)
KR (1) KR20210054500A (fr)
CN (1) CN112789287B (fr)
AR (1) AR116663A1 (fr)
AU (2) AU2019294261B2 (fr)
BR (1) BR112020026663A2 (fr)
CA (1) CA3103158A1 (fr)
CO (1) CO2020016080A2 (fr)
DK (1) DK3810633T3 (fr)
EA (1) EA202092819A1 (fr)
ES (1) ES2971732T3 (fr)
FI (1) FI3810633T3 (fr)
HR (1) HRP20240028T1 (fr)
HU (1) HUE065134T2 (fr)
IL (1) IL279620A (fr)
LT (1) LT3810633T (fr)
MA (1) MA52946B1 (fr)
MD (1) MD3810633T2 (fr)
MX (1) MX2020013811A (fr)
PH (1) PH12020552240A1 (fr)
PL (1) PL3810633T3 (fr)
PT (1) PT3810633T (fr)
RS (1) RS65128B1 (fr)
SG (1) SG11202012747VA (fr)
SI (1) SI3810633T1 (fr)
UA (1) UA128162C2 (fr)
WO (1) WO2020002325A1 (fr)
ZA (1) ZA202301937B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI757229B (zh) * 2014-11-26 2022-03-11 美商斯佩羅治療學股份有限公司 用於治療微生物感染的化合物以及該化合物的用途
JP7488774B2 (ja) * 2018-06-25 2024-05-22 スペロ・セラピューティクス・インコーポレーテッド 化合物
WO2022098950A1 (fr) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Composés

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
WO1988000950A2 (fr) 1986-08-06 1988-02-11 Fauchere Jean Luc Fabrication de conjugues a liaisons de covalence a partir d'un antibiotique et d'un derive non toxique de la polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (fr) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
NZ546344A (en) 2003-09-30 2010-04-30 Terry Hicks Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
KR20150008198A (ko) 2006-08-11 2015-01-21 노던 안티바이오틱스 리미티드 폴리믹신 유도체들 및 이들의 용도
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
US8343912B2 (en) 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (fr) 2009-05-14 2010-11-18 Monash University Composés antimicrobiens
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (fr) 2010-10-21 2012-04-26 Monash University Composés antimicrobiens
WO2012168820A1 (fr) 2011-06-08 2012-12-13 Pfizer Inc. Dérivés de polymyxine utiles en tant qu'agents antibactériens
US9234006B2 (en) 2011-11-18 2016-01-12 Novacta Biosystems Limited Compounds
RU2730012C2 (ru) 2013-05-22 2020-08-14 Сперо Терапьютикс, Инк. Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
TWI709575B (zh) 2014-03-11 2020-11-11 美商斯佩羅治療學股份有限公司 多黏菌素衍生物以及其與不同抗生素一起之組合療法的用途
JP2017512818A (ja) 2014-04-01 2017-05-25 モナシュ、ユニバーシティMonash University 抗菌性化合物としてのポリミキシン誘導体
TWI757229B (zh) 2014-11-26 2022-03-11 美商斯佩羅治療學股份有限公司 用於治療微生物感染的化合物以及該化合物的用途
WO2016166103A1 (fr) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Dérivés de polymyxine
US11225505B2 (en) * 2015-09-29 2022-01-18 Monash University Antimicrobial polymyxin derivative compounds
JP7488774B2 (ja) * 2018-06-25 2024-05-22 スペロ・セラピューティクス・インコーポレーテッド 化合物
WO2020014501A1 (fr) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions et procédés pour le traitement d'infections bactériennes

Also Published As

Publication number Publication date
CO2020016080A2 (es) 2021-01-18
IL279620A (en) 2021-03-01
EP3810633B1 (fr) 2023-12-13
AU2019294261A1 (en) 2021-02-04
WO2020002325A1 (fr) 2020-01-02
PT3810633T (pt) 2024-02-19
UA128162C2 (uk) 2024-04-24
US20230012121A1 (en) 2023-01-12
EP4316504A3 (fr) 2024-04-17
KR20210054500A (ko) 2021-05-13
JP7488774B2 (ja) 2024-05-22
PH12020552240A1 (en) 2021-08-16
PL3810633T3 (pl) 2024-04-08
CN112789287A (zh) 2021-05-11
SG11202012747VA (en) 2021-01-28
ES2971732T3 (es) 2024-06-06
MD3810633T2 (ro) 2024-05-31
US20210246169A1 (en) 2021-08-12
EP4316504A2 (fr) 2024-02-07
EA202092819A1 (ru) 2021-05-21
EP3810633A1 (fr) 2021-04-28
MA52946B1 (fr) 2024-03-29
CA3103158A1 (fr) 2020-01-02
HRP20240028T1 (hr) 2024-03-29
RS65128B1 (sr) 2024-02-29
SI3810633T1 (sl) 2024-04-30
AU2024203362A1 (en) 2024-06-06
MX2020013811A (es) 2021-03-09
JP2024109664A (ja) 2024-08-14
HUE065134T2 (hu) 2024-05-28
FI3810633T3 (fi) 2024-02-09
BR112020026663A2 (pt) 2021-03-23
TW202019949A (zh) 2020-06-01
AU2019294261B2 (en) 2024-02-29
JP2021528449A (ja) 2021-10-21
US11459357B2 (en) 2022-10-04
AR116663A1 (es) 2021-06-02
CN112789287B (zh) 2024-06-21
DK3810633T3 (da) 2024-01-15
LT3810633T (lt) 2024-01-10
ZA202301937B (en) 2023-09-27

Similar Documents

Publication Publication Date Title
MA52489A (fr) Nouveaux composés
MA52948A (fr) Composés
MA49701A (fr) Composés immunomodulateurs
MA51669A (fr) Composés
MA52560A (fr) Composés hétéroaryles tétracycliques
MA53003A (fr) Composés
MA44233A (fr) Nouveaux composés
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA50504A (fr) Composés antibactériens
MA44020A (fr) Composés antitumoraux
MA49522A (fr) Nouveaux composés de quinoléinone
MA49621A (fr) Composés bifonctionnels
MA52946A (fr) Composés
MA53430A (fr) Nouveaux composés
MA51221A (fr) Composés de pyrazolopyridinone
MA49885A (fr) Composés macrocycliques
MA49880A (fr) Composés anticancéreux
MA56058A (fr) Composés tricycliques
MA43791A (fr) Composés de carbapénème
MA48946A (fr) Composés
MA50561A (fr) Composés inhibiteurs de btk
DK3752258T3 (da) Trampolin
MA54520A (fr) Composés anticancéreux
IT201900004161A1 (it) Composti fluoroarilossibenzoeterodiazolici disostituiti
DK3587968T3 (da) Fluidsystem